Your browser is no longer supported. Please, upgrade your browser.
ALLO [NASD]
Allogene Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.83 Insider Own2.30% Shs Outstand132.16M Perf Week-4.56%
Market Cap3.86B Forward P/E- EPS next Y-2.61 Insider Trans-3.34% Shs Float70.24M Perf Month-5.17%
Income-228.80M PEG- EPS next Q-0.54 Inst Own64.20% Short Float10.32% Perf Quarter-17.26%
Sales38.30M P/S100.69 EPS this Y-13.80% Inst Trans0.36% Short Ratio8.33 Perf Half Y0.90%
Book/sh8.09 P/B3.47 EPS next Y-19.70% ROA-18.70% Target Price49.00 Perf Year-16.02%
Cash/sh5.09 P/C5.51 EPS next 5Y1.00% ROE-20.60% 52W Range24.85 - 55.00 Perf YTD11.13%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-47.71% Beta-
Dividend %- Quick Ratio13.10 Sales past 5Y- Gross Margin- 52W Low15.73% ATR1.75
Employees265 Current Ratio13.10 Sales Q/Q- Oper. Margin- RSI (14)38.10 Volatility5.36% 5.61%
OptionableYes Debt/Eq0.00 EPS Q/Q50.00% Profit Margin- Rel Volume1.42 Prev Close28.05
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume870.00K Price28.76
Recom1.70 SMA20-10.19% SMA50-14.88% SMA200-14.69% Volume809,657 Change2.53%
Jan-26-21Upgrade Stifel Hold → Buy $33 → $43
Dec-10-20Resumed H.C. Wainwright Buy $40
Nov-24-20Initiated BofA Securities Buy $41
Oct-23-20Initiated RBC Capital Mkts Outperform $55
Jun-01-20Downgrade Raymond James Outperform → Mkt Perform
May-29-20Reiterated H.C. Wainwright Buy $42 → $55
May-19-20Upgrade ROTH Capital Neutral → Buy $26 → $60
May-15-20Upgrade Guggenheim Neutral → Buy
May-14-20Reiterated H.C. Wainwright Buy $35 → $42
May-14-20Downgrade SunTrust Buy → Hold $29 → $32
Apr-13-20Initiated SunTrust Buy $29
Mar-13-20Initiated H.C. Wainwright Buy $35
Mar-05-20Initiated Stifel Hold $27
Feb-24-20Initiated Berenberg Hold $27
Dec-18-19Initiated JMP Securities Mkt Outperform $37
Nov-04-19Initiated Canaccord Genuity Buy $36
Aug-09-19Initiated BTIG Research Buy $37
Jun-05-19Initiated ROTH Capital Neutral $26
May-31-19Initiated Guggenheim Neutral
May-23-19Initiated Stifel Hold
May-12-21 08:30AM  
May-06-21 10:24AM  
May-05-21 06:05PM  
04:02PM  
03:15PM  
01:36AM  
Apr-28-21 09:24AM  
Apr-27-21 08:30AM  
Apr-22-21 10:25AM  
Apr-21-21 08:30AM  
Apr-19-21 08:30AM  
Apr-12-21 08:30AM  
Apr-10-21 08:30AM  
Mar-27-21 11:31AM  
Feb-26-21 08:57AM  
Feb-25-21 04:02PM  
03:15PM  
Feb-18-21 08:30AM  
Feb-09-21 08:30AM  
Jan-26-21 08:30AM  
Jan-10-21 11:35PM  
Jan-05-21 08:30AM  
Dec-24-20 10:47AM  
Dec-23-20 11:30AM  
Dec-18-20 09:30PM  
Dec-15-20 06:00AM  
Dec-07-20 12:40PM  
10:00AM  
Dec-06-20 10:00AM  
Dec-05-20 12:30PM  
Dec-04-20 11:31AM  
Dec-02-20 08:30AM  
Nov-12-20 08:30AM  
Nov-08-20 11:04AM  
Nov-04-20 12:44PM  
09:52AM  
09:03AM  
07:30AM  
06:45AM  
Oct-27-20 08:30AM  
Oct-24-20 08:55AM  
Oct-21-20 10:02AM  
Oct-15-20 08:00AM  
Sep-29-20 06:48PM  
Sep-04-20 11:31AM  
Sep-02-20 08:30AM  
Aug-06-20 11:19AM  
Aug-05-20 07:30AM  
Jul-29-20 09:27AM  
Jul-28-20 08:30AM  
Jul-20-20 08:30AM  
Jul-15-20 07:55AM  
Jul-07-20 08:30AM  
Jul-05-20 03:31PM  
Jul-01-20 10:54AM  
08:30AM  
Jun-26-20 03:30PM  
11:30AM  
Jun-22-20 04:30PM  
08:30AM  
Jun-14-20 11:38AM  
07:00AM  
Jun-10-20 11:30AM  
Jun-05-20 11:32AM  
Jun-03-20 08:30AM  
Jun-02-20 07:14AM  
Jun-01-20 09:05PM  
11:52AM  
06:30AM  
06:02AM  
May-29-20 10:32AM  
08:00AM  
May-28-20 11:21AM  
May-27-20 10:02AM  
May-26-20 04:30PM  
May-22-20 11:30AM  
May-19-20 08:55AM  
May-18-20 09:22AM  
May-15-20 07:49AM  
May-14-20 01:06PM  
04:20AM  
May-13-20 05:00PM  
10:54AM  
May-11-20 08:30AM  
May-07-20 10:51AM  
08:01AM  
May-06-20 07:30AM  
May-05-20 11:45AM  
11:40AM  
08:43AM  
Apr-29-20 11:54AM  
11:43AM  
Apr-28-20 04:39PM  
Apr-27-20 08:30AM  
Apr-22-20 07:15AM  
Apr-17-20 11:30AM  
Apr-16-20 12:00PM  
Apr-01-20 08:30AM  
Mar-28-20 09:10PM  
Mar-24-20 07:00AM  
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was founded in 2017 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bhavnagri VeerGeneral CounselApr 15Option Exercise2.2710,00022,700431,353Apr 16 04:07 PM
Bhavnagri VeerGeneral CounselApr 15Sale32.0510,000320,517421,353Apr 16 04:07 PM
Bhavnagri VeerGeneral CounselMar 15Option Exercise2.2710,00022,700415,774Mar 17 05:00 PM
Bhavnagri VeerGeneral CounselMar 15Sale37.9516,623630,798399,151Mar 17 05:00 PM
Chang David DPresident and CEOMar 15Sale38.5720,513791,2712,204,417Mar 17 05:00 PM
Amado RafaelEVP of R&D and CMOMar 15Sale38.052,798106,471110,035Mar 17 05:01 PM
SCHMIDT ERIC THOMASChief Financial OfficerMar 15Sale38.238,053307,88971,231Mar 17 05:00 PM
MOORE ALISONChief Technical OfficerMar 15Sale38.146,164235,089102,574Mar 17 05:00 PM
SCHMIDT ERIC THOMASChief Financial OfficerJan 15Sale32.2615,000483,8591,152,595Jan 19 04:31 PM
SCHMIDT ERIC THOMASChief Financial OfficerJan 14Sale30.7715,000461,6101,167,595Jan 19 04:31 PM
Bhavnagri VeerGeneral CounselDec 17Option Exercise2.2751,500116,905405,402Dec 18 04:34 PM
SCHMIDT ERIC THOMASChief Financial OfficerNov 16Sale32.8815,000493,1461,182,595Nov 18 04:36 PM
SCHMIDT ERIC THOMASChief Financial OfficerOct 15Sale40.4915,000607,3921,197,595Oct 16 06:55 PM
MOORE ALISONChief Technical OfficerOct 13Option Exercise2.2711,03125,040119,401Oct 13 04:34 PM
MOORE ALISONChief Technical OfficerOct 13Sale42.0011,031463,302108,370Oct 13 04:34 PM
MOORE ALISONChief Technical OfficerOct 12Option Exercise2.2724,23355,009132,603Oct 13 04:34 PM
MOORE ALISONChief Technical OfficerOct 12Sale42.0024,2331,017,786108,370Oct 13 04:34 PM
MOORE ALISONChief Technical OfficerOct 09Option Exercise2.2730,19968,552147,879Oct 09 05:49 PM
MOORE ALISONChief Technical OfficerOct 09Sale41.0039,5091,619,869108,370Oct 09 05:49 PM
MOORE ALISONChief Technical OfficerOct 08Option Exercise2.275,06511,498122,745Oct 09 05:49 PM
MOORE ALISONChief Technical OfficerOct 08Sale41.005,065207,665117,680Oct 09 05:49 PM
Amado RafaelEVP of R&D and CMOOct 07Sale39.4016,538651,515111,677Oct 08 05:10 PM
Bhavnagri VeerGeneral CounselOct 06Option Exercise2.2710,00022,700363,902Oct 08 05:01 PM
MOORE ALISONChief Technical OfficerOct 06Option Exercise2.2735,26480,049161,536Oct 08 05:03 PM
MOORE ALISONChief Technical OfficerOct 06Sale40.0044,5741,782,960117,680Oct 08 05:03 PM
Bhavnagri VeerGeneral CounselOct 06Sale40.0010,000400,000353,902Oct 08 05:01 PM
Bhavnagri VeerGeneral CounselOct 01Option Exercise2.2725,00056,750378,902Oct 02 04:42 PM
Bhavnagri VeerGeneral CounselOct 01Sale36.5225,000912,913353,902Oct 02 04:42 PM
Amado RafaelEVP of R&D and CMOOct 01Sale36.379,752354,662128,215Oct 02 04:40 PM
SCHMIDT ERIC THOMASChief Financial OfficerSep 21Sale35.3015,000529,5451,212,595Sep 22 04:48 PM
Bhavnagri VeerGeneral CounselSep 01Option Exercise2.2725,00056,750378,902Sep 03 04:12 PM
Bhavnagri VeerGeneral CounselSep 01Sale35.3625,000883,966353,902Sep 03 04:12 PM
MOORE ALISONChief Technical OfficerAug 13Option Exercise2.2732,45173,664126,272Aug 14 04:04 PM
TPG Group Holdings (SBS) Advis10% OwnerAug 07Sale37.4113,291497,23618,716,306Aug 10 04:34 PM
TPG Group Holdings (SBS) Advis10% OwnerAug 06Sale37.5024,154905,79418,729,597Aug 10 04:34 PM
Bhavnagri VeerGeneral CounselAug 03Option Exercise2.2725,00056,750385,455Aug 05 05:09 PM
Bhavnagri VeerGeneral CounselAug 03Sale36.8931,5531,164,121353,902Aug 05 05:09 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 30Sale42.2159,7472,522,05219,716,306Jun 30 04:53 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 29Sale43.2724,9041,077,54419,776,053Jun 30 04:53 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 26Sale44.0150022,00519,800,957Jun 30 04:53 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 25Sale44.1972,3593,197,32719,801,457Jun 25 06:24 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 24Sale43.9315,269670,71419,873,816Jun 25 06:24 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 23Sale43.98132,2255,814,61019,889,085Jun 25 06:24 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 22Sale42.83172,4257,384,72120,021,310Jun 22 06:25 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 19Sale42.0447,7672,008,30620,193,735Jun 22 06:25 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 18Sale42.1494,6003,986,59520,241,502Jun 22 06:25 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 17Sale42.1887,3193,683,48220,336,102Jun 17 06:13 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 16Sale42.20174,5117,364,67820,423,421Jun 17 06:13 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 15Sale42.14129,1545,442,88520,597,932Jun 17 06:13 PM
Belldegrun ArieDirectorJun 04Buy47.00146,3826,879,9541,798,163Jun 04 04:04 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 04Sale47.111,81885,63820,727,086Jun 05 05:43 PM
TPG Group Holdings (SBS) Advis10% OwnerJun 03Sale47.40487,40223,102,51420,728,904Jun 05 05:43 PM